Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Has “Reasonable” Chance Of Launching Its Long-Acting EPO In U.S.

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche believes is has a "reasonable" chance of being able to launch its long-acting EPO product CERA in the U.S. upon approval despite expected patent challenges, the company said Sept. 13 at the Bear Stearns health care conference in New York.

You may also be interested in...



Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks

CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.

Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks

CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.

Roche Gearing For CERA Renal Anemia BLA In 2006

Roche readies CERA long-acting anti-anemia therapy BLA for 2006 filing. Four Phase III trials meet primary endpoint of hemoglobin maintenance.

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel